Binding characteristics of fluoroquinolones to synthetic levodopa melanin.
To define the binding characteristics of fluoroquinolones to synthetic levodopa melanin, the binding of various drugs, including levofloxacin and ofloxacin, and positive controls (timolol and chloroquine), was investigated in-vitro. The affinity and capacity of the drug binding were calculated by Langmuir's adsorption isotherm. The affinity constant (K) and the binding capacity (r(max)) of levofloxacin were similar to those of timolol and much lower than those of chloroquine. Racemic ofloxacin and its enantiomers showed similar K and r(max), suggesting that the binding lacked stereoselectivity. The binding experiment with levofloxacin derivatives indicated that the basic nitrogen atom at position 7 of the quinolone ring, but not carboxyl group at position 3, would play a critical role in the interaction of fluoroquinolones with melanin. The melanin-drug complexes of levofloxacin and chloroquine were washed with neutral phosphate buffer, ethanol and 1 M HCl solution to explain the nature of the interaction of melanin with the drugs. Electrostatic forces mainly participate in the formation of the chloroquine-melanin complex, whereas van der Waals' and hydrophobic interactions are involved in the levofloxacin-melanin complex in addition to electrostatic forces. The interactions of various fluoroquinolones such as norfloxacin, enoxacin, sparfloxacin, ciprofloxacin and lomefloxacin with melanin were also studied. The results showed that the relative K value was: chloroquine approximately ciprofloxacin, sparfloxacin >/= lomefloxacin > timolol, levofloxacin approximately enoxacin, norfloxacin, and that the relative r(max) value was: norfloxacin, enoxacin >/= chloroquine, sparfloxacin > levofloxacin, ciprofloxacin, timolol, lomefloxacin. The fluoroquinolones vary in their affinity and capacity to bind with melanin, and ciprofloxacin and sparfloxacin showed a stronger interaction with melanin than the other fluoroquinolones studied.
Ono
Chiho
C
Drug Metabolism and Physicochemical Property Research Laboratory, Daiichi Pharmaceutical Co., Ltd, 16-13, Kita-Kasai 1-Chome, Edogawa-ku, Tokyo 134-8630, Japan.
Tanaka
Makoto
M
D001665:Binding Sites / Q000187:drug effects*; D002738:Chloroquine / Q000737:chemistry / Q000493:pharmacokinetics; D002939:Ciprofloxacin / Q000737:chemistry / Q000493:pharmacokinetics; D004347:Drug Interactions / Q000502:physiology; D015365:Enoxacin / Q000737:chemistry / Q000493:pharmacokinetics; D024841:Fluoroquinolones / Q000737:chemistry* / Q000493:pharmacokinetics*; D007980:Levodopa / Q000737:chemistry*; D064704:Levofloxacin; D008543:Melanins / Q000493:pharmacokinetics*; D014442:Monophenol Monooxygenase / Q000737:chemistry*; D009643:Norfloxacin / Q000737:chemistry / Q000493:pharmacokinetics; D015242:Ofloxacin / Q000737:chemistry / Q000493:pharmacokinetics; D015363:Quinolones / Q000737:chemistry / Q000493:pharmacokinetics; D013999:Timolol / Q000737:chemistry / Q000493:pharmacokinetics
D024841:Fluoroquinolones; D008543:Melanins; D015363:Quinolones; D015365:Enoxacin; D007980:Levodopa; D002939:Ciprofloxacin; D064704:Levofloxacin; D013999:Timolol; D002738:Chloroquine; D015242:Ofloxacin; D014442:Monophenol Monooxygenase; C053091:lomefloxacin; D009643:Norfloxacin; C061363:sparfloxacin